Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PUL-042 for COVID-19 Treatment
NCT04312997Phase 2Completed
- Sponsor
- Pulmotect
- Start
- Jun 2020
- Primary completion
- Jul 2021
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of PUL-042 in coronavirus disease 2019 (COVID-19), sponsored by Pulmotect. Started Jun 2020; status: completed.
02
Drugs
PUL-042
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04312997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04312997.